KEAP1 Fusion Protein
e coli.-derived, PGEX-4T
Cat no : Ag0779
INrf2; KIAA0132; KLHL19; MGC10630; MGC1114; MGC20887; MGC4407; MGC9454
(325-624 aa encoded by BC002930)
|Endotoxin Level||Please contact the lab for more information.|
|Purity||90%, by SDS-PAGE with Coomassie Brilliant Blue staining.|
|Formulation||The purified protein was Lyophilized from sterile PBS (58mM Na2HPO4,17mM NaH2PO4, 68mM NaCl, pH8.). 5 % trehalose and 5 % mannitol are added as protectant before lyophilization. The elution buffer contain 100mM GSH.|
Reconstitution and Storage
Reconstitute at 0.25 µg/μl in 200 μl sterile water for short-term storage.
Reconstitution with 200 μl 50% glycerol solution is recommended for longer term storage (see Stability and Storage for more details).
If a different concentration is needed for your purposes please adjust the reconstitution volume as required (please note: the ion concentration of the final solution will vary according to the volume used).
Note: Centrifuge vial before opening. When reconstituting, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution.
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature (see below).|
|Stability and Storage||Store for up to 12 months at -20°C to -80°C as lyophilized powder.|
|Storage of Reconstituted Protein||
Short-term storage: Store at 2-8°C for (1-2 weeks).
Long-term storage: Aliquot and store at -20°C to -80°C for up to 3 months, buffer containing 50% glycerol is recommended for reconstitution. Avoid repeat freeze-thaw cycles.
Oxid Med Cell Longev
JFD, a Novel Natural Inhibitor of Keap1 Alkylation, Suppresses Intracellular Mycobacterium Tuberculosis Growth through Keap1/Nrf2/SOD2-Mediated ROS Accumulation
Free Radic Biol Med
Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis.
Free Radic Biol Med
BP5 alleviates endotoxemia-induced acute lung injury by activating Nrf2 via dual regulation of the Keap1-Nrf2 interaction and the Akt (Ser473)/GSK3β (Ser9)/Fyn pathway
Eur J Med Chem
Briarane-type diterpenoids, the inhibitors of osteoclast formation by interrupting Keap1-Nrf2 interaction and activating Nrf2 pathway
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model